Phase III Open Label Trial for Use of [18F]-Fluoro-Deoxy-Glucose (18F-FDG) in Positron Emission Tomography Imaging in Oncology
Positron emission tomography (PET) is a nuclear medicine procedure based on the measurement
of positron emission from radiolabelled tracer molecules. These radiotracers allow biologic
processes to be measured and whole body images to be obtained which demonstrates sites of
radiotracer accumulation. The most common radiotracer in use today is 18F-fluorodeoxyglucose
(18F-FDG) which is a radiolabelled sugar (glucose) molecule. Imaging with 18F-FDG PET is
used to determine sites of abnormal glucose metabolism and can be used to characterize and
localize many types of tumours.
Cancer treatment and outcome depend largely on the accurate diagnosis and staging of
disease. There is extensive data in the literature indicating the importance of FDG-PET
imaging in accurately characterizing disease, as well as determining stage and sites of
recurrent disease in many cancer types. For these indications, functional imaging with PET
provides unique information which is not available from standard medical imaging modalities
such as ultrasound, X-ray, computerized tomography (CT) or magnetic resonance imaging (MRI).
The objectives of this study are to document the safety and efficacy of 18F-FDG produced by
the British Columbia Cancer Agency (BCCA) at its Tri-University Meson Facility (TRIUMF)
production facility and to evaluate FDG-PET as a diagnostic and decision making tool in the
management of oncology patients in British Columbia. With a population base of over 4
million people, standardized cancer treatment protocols, and evidence based guidelines for
FDG-PET imaging, the BCCA is positioned to make an important contribution to defining the
role of PET in the Canadian health care system.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society